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Abstract
Background: One of the major reasons for poor prognosis of pancreatic cancer is its high
resistance to currently available chemotherapeutic agents. In recent years, focal adhesion kinase
(FAK), a central molecule in extracellular matrix (ECM)/integrin-mediated signaling, has been
thought to be a key determinant of chemoresistance in cancer cells. In this study, we aimed to
determine the roles of FAK phosphorylation in the intrinsic chemoresistance of pancreatic cancer
cell lines.
Results: Our results showed that, the level of constitutive phosphorylation of FAK at Tyr397
correlated with the extent of intrinsic resistance to Gemcitabine (Gem) in four pancreatic cancer
cell lines. Moreover, in Panc-1 cells, which had high expression of pFAK, specific inhibition of
constitutive FAK phosphorylation by either RNAi or FRNK overexpression decreased the
phosphorylation of Akt, reduced the levels of survivin expression and Bad phosphorylation at
Ser136 and increased Gem-induced cytotoxicity and apoptosis. However, in AsPC-1 cells with a
low level of pFAK, neither FAK RNAi nor FRNK overexpression affected Gem-induced cell
apoptosis. We further found that laminin (LN) induced FAK and Akt phosphorylation in a time-
dependent manner, increased the levels of survivin and pBad (pS136) and decreased Gem-induced
cytotoxicity and apoptosis in AsPC-1 cells; Specific inhibition of LN-induced FAK phosphorylation
by either FAK RNAi or FRNK overexpression suppressed the effects of LN on AsPC-1 cells.
Moreover, inhibition of constitutive FAK phosphorylation in Panc-1 cells and LN-induced FAK
phosphorylation in AsPC-1 cells by a novel and more specific FAK phosphorylation inhibitor PF-
573,228 showed similar results with those of FAK phosphorylation inhibition by FAK RNAi or
FRNK overexpression.
Conclusions: In conclusion, our research demonstrates for the first time that both constitutive
and LN-induced FAK phosphorylation contribute to increased intrinsic chemoresistance to Gem
in pancreatic cancer cell lines and these effects are partly due to the regulation of Akt and Bad
phosphorylation and survivin expression. Development of selective FAK phosphorylation inhibitors
may be a promising way to enhance chemosensitivity in pancreatic cancer.
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Background
Pancreatic cancer is difficult to treat and patients have an
overall 5-year survival rate of <5% and a median overall
survival of <6 months [1,2]. Many tumors are already
unresectable at diagnosis due to metastasis or the presence
of locally advanced disease, and thus the majority of
patients are potential candidates for palliative treatment
including chemotherapy [3]. Gemcitabine (Gem) is cur-
rently the first line drug in the treatment of advanced pan-
creatic cancer [4,5]. However, due to high intrinsic
resistance of pancreatic cancer to currently available
agents, clinical trials have shown that Gem alone and
Gem-based combination chemotherapy are not likely to
achieve great success [3,4,6]. Therefore, new therapeutic
strategies are urgently needed. In pancreatic cancer, a
combination of conventional chemotherapies with new
therapies directly targeted against the molecular changes
in pancreatic cancer seems to be the most promising strat-
egy so far [7-9]. Tyrosine kinases have demonstrated great
promise as therapeutic targets for cancers, and combina-
tions of appropriate tyrosine kinase inhibitors (TKIs) with
cytotoxic agents such as Gem have been demonstrated to
improve the prognosis of pancreatic cancer [7,10,11].
Non-receptor tyrosine kinase focal adhesion kinase (FAK)
has been shown to be closely related to cancers. FAK
expression and (or) phosphorylation was elevated in a
variety of cancers and frequently correlated with malig-
nant or metastatic disease and poor patient prognosis
[12,13]. Moreover, the modulation of FAK expression and
(or) phosphorylation influences the sensitivity of tumor
cells to various chemotherapeutic agents, and combina-
tion of the selective FAK inhibitors with cytotoxic agents
might be a very promising anti-cancer therapy [14-16].
High FAK protein expression is also present in pancreatic
cancer, but not significantly related to clinicopathological
factors such as tumor histological grade, lymph node
metastasis, distant metastasis, histological stage, and over-
all survival in pancreatic cancer patients [17]. Besides the
regulation of FAK expression, another well-understood
mode of FAK regulation in cancer cells is phosphoryla-
tion, particularly tyrosine phosphorylation [18]. In this
study, we first investigated the correlation between the
level of constitutive FAK expression and phosphorylation
and the extent of chemoresistance in four pancreatic can-
cer cell lines.
As we know, RNAi downregulates protein expression and
thus activity. However, FAK related non-kinase (FRNK)
can compete with FAK for focal adhesion binding sites
and thus specifically inhibit FAK phosphorylation and
downstream signaling without changing expression [19-
21]. In our study, we used the two kinds of plasmids (FAK
RNAi plasmid and FRNK overexpression plasmid) to fur-
ther dissect the role of constitutive FAK phosphorylation
in the chemoresistance of pancreatic cancer cells that had
high level of pFAK.
Recently, a novel small molecule inhibitor, PF-573,228
(here after referred to as PF-228), has been developed to
block FAK phosphorylation on Tyr397 and target FAK cat-
alytic activity, which provides an appropriate tool to dis-
sect the role of FAK phosphorylation [22]. Compared with
FRNK overexpression, PF-228 is a more specific method to
decrease FAK phosphorylation. Therefore, PF-228 was
used in our study to confirm the role of FAK phosphoryla-
tion in the chemoresistance of pancreatic cancer cells.
FAK is a key molecule in signal transduction from extracel-
lular matrix (ECM) to cells, and it has been reported in
recent years that the intrinsic chemoresistance of tumor
cells could be induced by ECM-integrin interactions,
named cell adhesion-mediated drug resistance (CAM-DR)
[23]. Laminin (LN) has been confirmed to be one of the
most effective ECM proteins to induce CAM-DR [24-26].
Thus we further explored the role of LN on FAK phospho-
rylation and the intrinsic chemoresistance in the pancre-
atic cell line with low level of constitutive FAK
phosphorylation.
Methods
Antibodies and reagents
Rabbit polyclonal antibodies to pERK1/2, ERK1/2,
pAkt(pS473), AKT, pBad(pS112), pBad(pS136) and Bad
were from Cell Signaling Technology (Beverly, MA, USA).
Mouse monoclonal antibody (mAb) to pFAK (pY397)
was purchased from BD Biosciences PharMingen (San
Diego, CA, USA). FAK and FRNK (the carboxyl terminus
of FAK) proteins, were detected by mAb raised against
amino acids 903-1052 of human-origin FAK (Santa Cruz
Biotechnology, Santa Cruz, CA, USA). Anti-β-actin, anti-
Bcl-2, anti-Bax, anti-survivin, anti-caspase-3 primary anti-
bodies and HRP-conjugated secondary antibodies were all
purchased from Santa Cruz.
Gem was purchased from Eli Lilly (Indianapolis, IN,
USA). 5-Fluorouracil (5-FU), MTT, insulin, transferrin,
selenium, BSA and LN were all supplied by Sigma-Aldrich
Chemical (Poole, UK). The FAK inhibitor PF-573,228 was
purchased from Tocris (Bristol, UK).
Cell culture, transfection and generation of stable clones
Pancreatic cancer cell lines were all purchased from ATCC
(Rockville, MD, USA). AsPC-1, Panc-1 and BxPC-3 were
grown in RPMI 1640 (Invitrogen, Carlsbad, CA, USA)
supplemented with 10% (v/v) heat-inactivated fetal calf
serum (Gemini Bio-Products, Woodland, CA, USA),
whereas MiaPaCa-2 cells were grown in DMEM. All cells
were maintained at 37°C in a humidified atmosphere
with 5% CO2. Cell viability was routinely checked afterMolecular Cancer 2009, 8:125 http://www.molecular-cancer.com/content/8/1/125
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passage by trypan blue exclusion and was consistently
>95%. In all experiments with Gem or 5-FU, cells were
allowed to settle for 6 h prior to treatment.
Linearized pcDNA 6.2-GW/EmGFP-miR vector (Invitro-
gen) which enables increasing knockdown of a single tar-
get gene with one construct was used for vector-based
RNAi interference (RNAi) analysis. This vector can express
microRNA for RNAi analysis in most mammalian cells
using the human cytomegalovirus immediate early pro-
moter. Criteria for the selection of the target sequence
were as we described previously [27]. Plasmid construc-
tion was performed following the manufacturer's instruc-
tions. The RNAi vectors (FAK RNAi1, FAK RNAi2) were
generated by ligating the annealed DNA oligos into the
linearized vector and used to inhibit human FAK gene
(GenBank: NM_153831.2). The control vector pcDNA
6.2-GW/EmGFP-miR-neg encodes an mRNA not to target
any known vertebrate gene. The annealed oligos in FAK
RNAi1 plasmid were:
5'TGCTGAGAAATTTCTCTCTCACGCTGGTTTTGGCCACT
GACTGACCAGCGTGAGAGAAATTTCT3' (top strand)
5'CCTGAGAAATTTCTCTCACGCTGGTCAGTCAGTGGCCA
AAACCAGCGTGAGAGAGAAATTTCTC3' (bottom strand).
The annealed oligos in FAK RNAi2 plasmid were:
5'TGCTGTTCACCTTCTTTCTGAGGTCTGTTTTGGCCACT
GACTGACAGACCTCAAAGAAGGTGAA 3' (top strand)
5'CCTGTTCACCTTCTTTGAGGTCTGTCAGTCAGTGGCC
AAAACAGACCTCAGAAAGAAGGTGAAC 3' (bottom
strand).
FRNK was PCR amplified from the pRKvsv-FRNK plasmid
that was kindly provided by Dr. Kenneth M. Yamada
(National Institutes of Health, Bethesda, MD, USA) using
the following forward and reverse primers:
5'TCCGGATCCATGGAATCCAGAAGACAGGCTAC 3' and
5'CCGGAATTCTCAGTGTGGCCGTGTCTGCCCTA3'. The
PCR products were digested with BamHI and EcoRI and
cloned into pcDNA3.1 to generate pcDNA3.1-FRNK plas-
mid. Empty pcDNA3.1 plasmid was used as control.
Cells were transiently transfected using Lipofectamine
2000 reagent (Invitrogen) as suggested by the manufac-
turer. Stable clones were selected for blasticidin (pcDNA
6.2-GW/EmGFP-miR) or G418 (pcDNA3.1) resistance
using standard protocols [27]. Pools of four individual
clones were used to avoid artifacts. Parental cells and
pools transfected with vector plasmids were used as con-
trols. G418 or blasticidin was removed from the culture
media 24 h before functional assays.
Culture of cells on LN
Cell culture plastics were coated with LN (10 μg/cm2) for
2 h at 37°C. LN-coated dishes were rinsed three times
with PBS. In all experiments using LN, cells were serum
starved for 24 h before the experiments were performed.
Cells were then distributed onto LN-coated (LN) or con-
trol (plastic) wells and cultured in SITA medium (RPMI
1640 supplemented with 30 nM selenium, 5 μg/ml insu-
lin, 10 μg/ml transferrin, 0.25% (w/v) BSA, 100 U/ml
penicillin and 100 μg/ml streptomycin).
Western blotting
Cells were treated as specified and then lysated in RIPA
buffer (Pierce Biotechnology, Rockford, IL, USA) with
protease inhibitor mixture tablets and phosphatase inhib-
itor mixture tablets PhosSTOP (Roche Applied Science,
Mannheim, Germany). Protein concentration was deter-
mined by the BCA assay (Pierce). The whole-cell lysates
were heat denatured at 100°C for 10 min before being run
on 8-12% gradient SDS-PAGE. After SDS-PAGE, the pro-
teins were electrotransferred onto nitrocellulosemem-
branes, blotted with each primary antibody, incubated in
secondary antibody and then detected with enhanced
chemiluminescence reagent (Amersham Pharmacia Bio-
tech, Bucks, UK) and BioMax MR-1 radiographic film
(Kodak, Xiamen, China). Semi-quantitative analysis of
band intensities was performed by densitometry using
image analysis software Image Pro-Plus (Media Cybernet-
ics, Silver Spring, MD, USA).
Immunofluorescence
Cells were grown on glass coverslips and fixed with 4%
paraformaldehyde for 20 min at room temperature. Fixed
cells were then incubated with the primary anti- pFAK
(pY397) antibodies overnight, washed with PBS, and
incubated again with secondary antibodies conjugated
with FITC (green) for 1 h at room temperature. Hoechst
33342 was used to stain the nuclei (blue). Cells incubated
with secondary antibodies alone were used as controls.
The coverslips were mounted onto slides and cells were
viewed by a Leica TCS-SP2 confocal scanning microscope
(Leica Microsystems Heidelberg GmbH, Germany).
Cell viability assay
Cell viability was determined by MTT assay. Logarithmi-
cally growing cells were plated at 5 × 103 per well in 96-
well plates and allowed to adhere for 6 h. The cells were
then cultured in the absence or presence of different con-
centrations of 5-FU or Gem for the indicated time as spec-
ified in the Results. After treatment, 10 μL of the MTT was
added to each well to assess the cell viability, and after 4 h
at 37°C, the purple-blue MTT formazan precipitate was
dissolved in 100 μl of DMSO, and the optical density was
measured at 570 nm with a Vmax microplated spectro-
photometer (Molecular Devices, Sunnyvale, CA). Each
experiment was repeated at least thrice in quadruplicate.Molecular Cancer 2009, 8:125 http://www.molecular-cancer.com/content/8/1/125
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The concentration of Gem required to inhibit cell prolif-
eration by 50% (IC50) was calculated using Microsoft
Excel software for semi-log curve fitting with regression
analysis.
Clonogenic assay
Colony formation was evaluated using a soft agar clono-
genic-forming assay. A volume of 0.5 ml of RPMI1640
containing 10% fetal bovine serum and 0.5% agar was
plated on the bottom of 24-well plates. The plates were
stored at 4°C to allow the agar to freeze. Cells were treated
as specified in the Results, mixed with RPMI1640 contain-
ing 10% fetal bovine serum and 0.35% agar and plated
onto the 24-well plates that were prepared earlier at 500
cells per well (three wells per group). The plates were then
transferred to 37°C. After 14-18 days, colonies were man-
ually counted using a microscope and also visualized by
MTT stain.
Analysis of apoptosis by nuclear morphology
Apoptosis was judged by nuclear condensation. Distilled
slides were placed onto the surface of 6-well plates, and
then coated or not with LN as described above. Cells were
seeded onto the slides, allowed to settle for 6 h and then
treated with or without Gem for the indicated time. After
treatment, slides were washed with PBS, and cells were
fixed with 4% polyformaldehyde for 10 min. The slides
were washed again with PBS, and 0.1 ml of Hoechst
33342 at a concentration of 2 μg/ml was added to each
slide and incubated in the dark at room temperature for
15 min. The slides were washed three times with PBS, and
the cells were examined using a Motic fluorescence micro-
scope and photographed.
Flow cytometric assay of apoptosis
Phosphatidylserine externalization was analyzed with
Annexin-V-FITC/PI kit (BD) by a FACSCalibur flow
cytometer (BD) for cell apoptosis according to the manu-
facturer's instructions.
Statistical analysis
Results were expressed as the mean ± SE, and statistical
differences between groups in these assays were calculated
using a Student's two-tailed t test. Significance was
defined as P < 0.05 using a two-sided analysis.
Results
The level of constitutive phosphorylation of FAK at Tyr397 
correlates with the extent of intrinsic chemoresistance to 
Gem in pancreatic cancer cell lines
Western blot was used to determine constitutive FAK and
pFAK (pY397) expression in four pancreatic cancer cell
Constitutive phosphorylation of FAK at Tyr397 in pancreatic cancer cells Figure 1
Constitutive phosphorylation of FAK at Tyr397 in pancreatic cancer cells. A, Western blot analysis was performed 
to determine the constitutive level of total FAK and pFAK (pY397) expression in BxPC-3, AsPC-1, MiaPaCa-2 and Panc-1 cells. 
Equal protein loading was confirmed by β-actin. This figure shows a representative blot of an experiment performed in tripli-
cate. B, For semiquantitation, the intensities of FAK, pFAK and β-actin bands for each cell line were calculated using a densito-
meter. Bars are mean ± SE of relative FAK/β-actin or pFAK/FAK ratio (normalized to that for BxPC-3 cells, which was given a 
value of 1) for three independent experiments. C, Confocal microscopy images of the four pancreatic cancer cell lines showing 
constitutive expression of pFAK (pY397; green) to evaluate FAK phosphorylation status. The same fields stained with Hoechst 
33342 (blue) to indicate the position of nuclear DNA are shown in the middle panels and the merged images are shown in the 
bottom panels.Molecular Cancer 2009, 8:125 http://www.molecular-cancer.com/content/8/1/125
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lines (BxPC-3, AsPC-1, MiaPaCa-2 and Panc-1) (Fig. 1A-
B). Comparable protein levels of total FAK were found in
these cell lines, whereas different levels of constitutive
FAK phosphorylation were detected in these cell lines.
Panc-1 displayed a relatively high level of pFAK (pY397),
while MiaPaCa-2 and BxPC-3 cells displayed moderate
levels. FAK phosphorylation was lowest in AsPC-1 cells.
The different levels of constitutive FAK phosphorylation
were further supported by confocal microscopy showing
specific peripheral staining of pFAK (pY397) at focal
adhesion points (Fig. 1C). Specific pFAK (pY397) staining
was more obvious in Panc-1 cells than in the other three
cell lines, and little specific staining was observed in AsPC-
1 cells.
MTT assays demonstrated that cells with higher levels of
constitutive pFAK (pY397) also showed higher intrinsic
chemoresistance to Gem treatment (Fig. 2). The IC50 of
Gem for Panc-1 cells (58.24 μM) was approximately 5
times higher than that for MiaPaCa-2 cells (11.43 μM; P <
0.01), one log higher than that for BxPC-3 cells (5.91 μM;
P < 0.01) and two logs higher than that for AsPC-1 cells
(0.31 μM; P < 0.01). Spearman analysis showed that the
IC50 of Gem in these four cell lines significantly corre-
lated with the level of constitutive pFAK (pFAK/FAK ratio)
(r = 1; P < 0.05). There was no significant correlation
between pFAK level and the IC50 of 5-FU and between
total FAK protein level (FAK/β-actin ratio) and the IC50 of
Gem or 5-FU.
Taken together, these results suggested that constitutive
FAK phosphorylation was positively correlated with the
intrinsic chemoresistance to Gem in pancreatic cancer
cells.
Both FAK RNAi and FRNK overexpression decrease the 
phosphorylation of FAK and Akt in Panc-1 cells
We used two different kinds of plasmids to downregulate
FAK phosphorylation in Panc-1 cells, which had higher
constitutive pFAK (pY397) level. As expected, transient
transfection experiments showed that both methodologi-
cal approaches could inhibit FAK phosphorylation in
Panc-1 cells. Compared with nontransfection and vector-
transfection controls, transient transfection of RNAi plas-
mids (FAK RNAi1 and FAK RNAi2) resulted in downregu-
lation of FAK protein levels and subsequent reduction of
pFAK (pY397) levels (Fig. 3A), whereas transfection of
pcDNA3.1-FRNK plasmid decreased pFAK levels without
changing total FAK expression (Fig. 3B).
Individual clones and pools of Panc-1 cells transfected
with FAK RNAi2, pcDNA3.1-FRNK were obtained and
examined for total FAK and pFAK (pY397) expression.
Results observed in the stable clones were similar to the
transient transfection experiments (Fig. 3C-D). Akt and
ERK1/2 are two key kinases that are downstream of FAK,
and they are important for mediating cell survival. In
accord with decreased pFAK (pY397) levels, Panc-1 cells
stably transfected with either FAK RNAi2 or pcDNA3.1-
FRNK plasmid showed decreased Akt phosphorylation.
Intrinsic chemoresistance to Gem and 5-FU in pancreatic cancer cells Figure 2
Intrinsic chemoresistance to Gem and 5-FU in pancreatic cancer cells. The cell viability of BxPC-3, AsPC-1, Mia-
PaCa-2 and Panc-1 cells was determined by MTT assay after treatment with increasing doses of Gem or 5-FU for 72 h. And 
then IC50 was calculated.Molecular Cancer 2009, 8:125 http://www.molecular-cancer.com/content/8/1/125
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However, the levels of total Akt, total ERK1/2 and pERK1/
2 were not affected. RT-PCR analysis also showed that FAK
mRNA level was decreased in Panc-1 cells stably trans-
fected with FAK RNAi2 (data not shown).
These results confirmed that both FAK RNAi and FRNK
overexpression decreased the phosphorylation of FAK and
downstream kinase Akt in Panc-1 cells. To avoid artifacts
resulting from the use of single clones of transfected cells,
a pool of four individual clones was used for further
experiments.
Both FAK RNAi and FRNK overexpression enhance Gem-
induced cytotoxicity and apoptosis in Panc-1 cells
Cytotoxicity was determined by MTT and clonogenic
assays. Gem significantly inhibited Panc-1 cell viability in
a time-dependent manner (Fig. 4A, left). Stable pool cells
overexpressing FRNK had no significant difference in pro-
liferation compared with parental and vector cells. How-
ever, pool cells overexpressing FRNK demonstrated an
increased sensitivity to Gem treatment. After 72 h of Gem
treatment, the viability was approximately 20% lower in
pool cells overexpressing FRNK (P < 0.05) (Fig. 4A, right).
Similar results were obtained in clonogenic assays (Fig.
4B).
Apoptosis is considered as the major mechanism of chem-
otherapy-induced cell death [28]. We further determined
Effects of FAK RNAi and FRNK overexpression on the  expression and phosphorylation of FAK in Panc-1 cells Figure 3
Effects of FAK RNAi and FRNK overexpression on 
the expression and phosphorylation of FAK in Panc-1 
cells. Western blot analysis showed expression of FRNK, 
total FAK and pFAK (pY397) in Panc-1 cells transiently trans-
fected with FAK RNAi plasmids (FAK RNAi1 and FAK 
RNAi2) for five days (A) or pcDNA3.1-FRNK plasmid 
(FRNK) for three days (B). Parental cells and their respective 
vector-transfected (RNAi vector, vector) cells served as the 
control. C, FAK RNAi2 plasmid-transfected (i-Pool 1, i-
Clone 3) and vector-transfected (i-Vector) clones derived 
from Panc-1 cells were obtained using blasticidin as a selec-
tion marker. Western blot showed expression of pFAK 
(pY397), p-Akt (pS473), p-ERK 1/2 and their total proteins in 
the cells. D, pcDNA3.1-FRNK plasmid-transfected (Pool 1, 
Clone 2) and empty vector-transfected (Vector) clones were 
obtained using G418 as a selection marker. Western blot 
showed expression of pFAK (pY397), p-Akt (pS473), p-ERK 
1/2 and their total proteins in the cells. The membranes were 
probed with anti-β-actin antibody to ensure even loading of 
proteins in each lane.
Effects of FRNK overexpression on Gem-induced chemore- sistance in Panc-1 cells Figure 4
Effects of FRNK overexpression on Gem-induced 
chemoresistance in Panc-1 cells. A, The cell viability of 
parental Panc-1 cells and empty vector-transfected (Vector) 
and pcDNA3.1-FRNK plasmid-transfected (Pool 1) cells was 
determined by cell proliferation assays after treatment with 
or without 10 μM Gem for 24, 48 and 72 h. Results were 
expressed as the percentages of viable cells compared with 
parental cells without Gem treatment (left). The cell viability 
was statistically compared at 72 h after Gem treatment. Bars 
represent the mean of three independent experiments ± SE. 
*, P < 0.05, vs. parental cells without Gem treatment; #, P < 
0.05, vs. parental or vector cells with Gem treatment (right). 
B, Parental Panc-1 cells and vector and pool 1 cells were 
treated with or without 10 _M Gem for 24 h. Cells were 
then trypsinized and seeded in equal numbers into 24-well 
plates for clonogenic assay. After14 to 18 days, the mean 
number of the colonies was counted (left). The inhibition 
rate was defined by comparison of the colony number of 
each group with that of parental cells without Gem treat-
ment. Bars represent the mean of three independent experi-
ments ± SE. *, P < 0.05, vs. parental cells without Gem 
treatment; #, P < 0.05, vs. parental or vector cells with Gem 
treatment (right).Molecular Cancer 2009, 8:125 http://www.molecular-cancer.com/content/8/1/125
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the effects of FRNK overexpression on Gem-induced
apoptosis in Panc-1 cells. Cell apoptosis was analyzed by
Hoechst staining of nuclei, Annexin-V analysis of external-
ized phosphatidylserine and western blot analysis of
cleaved caspase-3 protein (Fig. 5A-D). Compared with
control groups, pool cells overexpressing FRNK were more
sensitive to Gem-induced apoptosis, which was demon-
strated by an increased proportion of condensed nuclei,
significantly higher of Annexin-V positivity (P < 0.05) and
more cleaved caspase-3 protein expression. However,
FRNK overexpression did not significantly affect the apop-
tosis of Panc-1 cells in the absence of Gem. Apoptosis-
associated proteins Bax, Bcl-2, BAD and survivin have all
been demonstrated to be involved in the chemoresistance
Effects of FRNK overexpression on Gem-induced apoptosis in Panc-1 cells Figure 5
Effects of FRNK overexpression on Gem-induced apoptosis in Panc-1 cells. Parental Panc-1 cells and empty vector-
transfected (Vector) and pcDNA3.1-FRNK plasmid-transfected (Pool 1) cells were treated with or without 10 μM Gem for 72 
h and subjected to cell apoptosis analysis by Hoechst staining (the arrow indicates the apoptotic cells) (A), flow cytometry anal-
ysis of Annexin-V labeling (B) and western blot analysis of cleaved caspase-3 protein expression (C). Bars represent the mean 
of three independent experiments ± SE. *, P < 0.05, vs. parental cells without Gem treatment; #, P < 0.05, vs. parental cells or 
vector cells with Gem treatment. D, Western blot analysis was used to detect the expression of Bad, p-Bad (pS136), p-Bad 
(pS112), Bcl-2, Bax and survivin in parental cells and vector and pool 1 cells. The membranes were probed with anti-β-actin 
antibody to ensure even loading of proteins in each lane.Molecular Cancer 2009, 8:125 http://www.molecular-cancer.com/content/8/1/125
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of pancreatic cancer cells and be regulated by FAK or Akt
[29-33]. Thus, we investigated whether inhibition of FAK
activity by FRNK overexpression might modulate these
proteins and thereby regulate apoptosis in Panc-1 cells.
Compared with parental cells and vector cells, clone 2 and
pool 1 cells transfected with pcDNA3.1-FRNK showed a
decrease in survivin expression and Bad phosphorylation
at Ser136 but did not affect Bax, Bcl-2 or Bad expression
or Bad phosphorylation at Ser112 (Fig. 5E). Similar
results were obtained in Panc-1 cells stably transfected
with the FAK RNAi2 plasmid (data not shown).
These results clearly showed that, inhibition of constitu-
tive FAK phosphorylation was sufficient to render Panc-1
cells more chemosensitive to Gem. It indicated that con-
stitutive pFAK was at least partially responsible for Gem
chemoresistance in pancreatic cancer lines and suggested
that the mechanisms might be related to survivin expres-
sion and pBad (pS136) level.
LN induces the phosphorylation of FAK and its 
downstream kinase Akt in AsPC-1 cells
AsPC-1 cells, which had lower level of FAK phosphoryla-
tion, were plated on LN for different time in SITA
medium. The levels of FAK, Akt and ERK phosphorylation
in cells were then examined (Fig. 6A-B). A low level of
constitutively activated FAK and Akt was found in AsPC-1
cells, and a rapid and strong stimulation of FAK and Akt
phosphorylation was induced by LN. The levels of phos-
phorylated FAK and Akt began to rise at 15 min and
peaked at 1 h after adhesion to LN, followed by a decline
over 24 h. In contrast, a significant basal level of phospho-
rylated ERK was observed in AsPC-1 cells, and no signifi-
cant change was induced by LN. The levels of total FAK,
Akt and ERK protein and pERK in AsPC-1 cells were all not
significantly affected by LN.
To determine whether LN-induced Akt activation in AsPC-
1 cells was dependent on FAK, pool cells transfected with
FAK RNAi2, pcDNA3.1-FRNK or their respective vector
control were obtained. The effect of LN on Akt activation
was almost completely blocked by inhibition of FAK
phosphorylation through either FAK RNAi or FRNK over-
expression (Fig. 7A-B).
These results indicated that in AsPC-1 cells, LN induced
FAK and Akt phosphorylation in a time-dependent man-
ner, and LN-induced Akt phosphorylation was mediated
by FAK activation.
LN suppresses Gem-induced cytotoxicity and apoptosis in 
AsPC-1 cells
Our results demonstrated that LN protected AsPC-1 cells
from Gem-induced cytotoxicity in a time-dependent man-
ner, and the protective effect was most obvious at 72 h
after Gem treatment (Fig. 8A). Colony-forming assays
Effect of LN on FAK phosphorylation and its downstream signaling kinases (Akt and ERK1/2) activity in AsPC-1 cells Figure 6
Effect of LN on FAK phosphorylation and its downstream signaling kinases (Akt and ERK1/2) activity in AsPC-
1 cells. A, AsPC-1 cells were treated as described in results for the indicated time and then subjected to western blot analysis 
to detect the expression of pFAK (pY397), p-Akt (pS473), p-ERK1/2 and their total proteins. The membranes were probed 
with anti-β-actin antibody to ensure even loading of proteins in each lane. B, For semiquantitation, the intensities of bands for 
each cell line were calculated using a densitometer. Bars are mean ± SE of relative pFAK/FAK, pAkt/Akt or pERK/ERK ratio 
(normalized to that of 0 min, which was given a value of 1) for three independent experiments.Molecular Cancer 2009, 8:125 http://www.molecular-cancer.com/content/8/1/125
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confirmed the protective effect of LN on Gem-induced
cytotoxicity (Fig. 8B).
Moreover, after Gem treatment, AsPC-1 cells plated on LN
demonstrated decreased apoptosis compared with those
on plastic (P < 0.05) (Fig. 9A-C). Data also revealed that
LN did not significantly protect cells without Gem treat-
ment from apoptosis.
LN also caused an increase in the expression of survivin
and the phosphorylation of Bad at Ser136 but did not
affect Bax, Bcl-2 or Bad expression or Bad phosphoryla-
tion at Ser112 in AsPC-1cells (Fig. 10D).
Collectively, these findings suggested that LN might medi-
ate the intrinsic chemoresistance to Gem in AsPC-1 cells.
Effects of FAK RNAi and FRNK overexpression on LN-
mediated Gem chemoresistance in AsPC-1 cells
When cultured on LN, pool cells expressing FRNK demon-
strated a significant increase in Gem-induced apoptosis,
compared with parental cells and vector cells (P < 0.05)
(Fig. 10A-C). However, FRNK overexpression did not sig-
nificantly affect Gem-induced apoptosis in AsPC-1 cells
on plastic (Fig. 10B). Moreover, inhibition of FAK phos-
phorylation by FRNK overexpression antagonized the
Effects of FAK RNAi and FRNK overexpression on LN-medi- ated FAK and Akt activation Figure 7
Effects of FAK RNAi and FRNK overexpression on 
LN-mediated FAK and Akt activation. After replating 
on plastic or LN for 1 h, parental AsPC-1 cells and FAK 
RNAi2-transfected pool cells (i-Pool) (A), pcDNA3.1-FRNK-
transfected pool cells (Pool) (B) and their respective vector-
transfected clones (i-Vector, Vector) were collected and 
used for western blot analysis to detect the expression of 
pFAK (pY397), p-Akt (pS473) and their total proteins. The 
membranes were probed with anti-β-actin antibody to 
ensure even loading of proteins in each lane.
Effects of LN on Gem-induced cytotoxity in AsPC-1 cells Figure 8
Effects of LN on Gem-induced cytotoxity in AsPC-1 cells. AsPC-1 cells were treated as described in results. A, The cell 
viability of AsPC-1 cells of different groups was determined by MTT assays. Results were expressed as the percentages of viable 
cells compared with cells on plastic without Gem treatment (left). The cell viability was statistically compared at 72 h after Gem 
treatment (right). B, The long-term clonogenic potential of pancreatic cancer cells was evaluated by clonogenic assay. AsPC-1 
cells on plastic or LN were treated with or without Gem (0.1 μM) for 24 h in SITA medium. Cells were then trypsinized and 
seeded in equal numbers into 24-well plates. After14 to 18 days, the mean number of the colonies was counted, and the inhibi-
tion rate was defined by comparison of the colony number of each group with that of cells on plastic without Gem treatment.Molecular Cancer 2009, 8:125 http://www.molecular-cancer.com/content/8/1/125
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effects of LN on survivin expression and Bad phosphoryla-
tion at Ser136 in AsPC-1 cells (Fig. 10D). Similar results
were observed with FAK RNAi in AsPC-1 cells (data not
shown). These results indicated that in AsPC-1 cells, LN-
induced FAK phosphorylation mediated the intrinsic
chemoresistance to Gem, and this effect might be related
with the regulation of survivin and pBad (pS136) level
Effects of PF-228 on Gem-induced apoptosis in pancreatic 
cancer cells
PF-228, a novel FAK inhibitor, has become available
recently. It specifically blocks FAK phosphorylation and
thus targets FAK catalytic activity. PF-228 is a more specific
method to decrease FAK phosphorylation compared with
FRNK overexpression. Therefore, in our study PF-228 was
further applied to confirm the role of FAK phosphoryla-
tion in the chemoresistance of pancreatic cancer cells.
We used PF-228 to downregulate constitutive FAK phos-
phorylation in Panc-1 cells and LN-induced FAK phos-
phorylation in Aspc-1 cells respectively. PF-228 could
inhibit both constitutive and LN-induced FAK phosphor-
ylation in a dose-dependent manner (Fig. 11A-B). 1 μM
PF-228 was sufficient to efficiently block both constitutive
FAK phosphorylation in Panc-1 cells and LN-induced FAK
phosphorylation in Aspc-1 cells. Consistent with the
results of FAK phosphorylation inhibition by FAK RNAi
and FRNK overexpression, specific inhibition of FAK
phosphorylation by PF-228 led to the corresponding inhi-
bition of AKT but not ERK phosphorylation in Panc-1
cells and Aspc-1 cells. The levels of total FAK, Akt and ERK
protein were not significantly affected.
We further determined the effects of PF-228 on Gem-
induced apoptosis in pancreatic cancer cells. Cell apopto-
sis was determined by methods as described above. Con-
sistent with the results of FAK RNAi and FRNK
overexpression, PF-228 rendered Panc-1 cells more sensi-
tive to Gem-induced apoptosis (Fig. 12A-C), while in
AsPC-1 cells PF-228 treatment antagonized LN-mediated
Gem chemoresistance (Fig. 13A-C), which was demon-
strated by an increased proportion of condensed nuclei,
significantly higher of Annexin-V positivity (P < 0.05) and
more cleaved caspase-3 protein expression. However, PF-
228 treatment alone did not significantly affect the apop-
Effects of LN on Gem-induced apoptosis in AsPC-1 cells Figure 9
Effects of LN on Gem-induced apoptosis in AsPC-1 cells. AsPC-1 cells were treated as described in results. After Gem 
treatment for 72 h, cell apoptosis was examined by Hoechst staining (the arrow indicates the apoptotic cells) (A), flow cytom-
etry analysis of Annexin-V labeling (B) and western blot analysis of cleaved caspase-3 protein expression (C). Bars represent 
the mean of three independent experiments ± SE. *, P < 0.05, vs. cells on plastic without Gem treatment; #, P < 0.05, vs. cells 
on plastic treated with Gem.Molecular Cancer 2009, 8:125 http://www.molecular-cancer.com/content/8/1/125
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tosis of Panc-1 cells on plastic or Aspc-1cells on LN. (Fig.
12C and 13C)
Consistent with the results of FAK RNAi and FRNK over-
expression, PF-228 decreased survivin expression and Bad
phosphorylation at Ser136 in Panc-1 cells and antago-
nized the effects of LN on survivin expression and Bad
phosphorylation at Ser136 in AsPC-1 cells (Fig. 14A-B).
These results further confirmed that, constitutive and LN-
induced FAK phosphorylation was at least partially
responsible for the intrinsic chemoresistance to Gem in
pancreatic cancer cells.
Discussion
Pancreatic cancer remains a major therapeutic challenge.
High resistance to chemotherapy is considered a common
phenomenon and one of the major reasons for poor prog-
nosis in pancreatic cancer [2]. Links between tyrosine
kinases and tumor chemoresistance have attracted more
and more attention in recent years [7]. The combination
of targeted therapy against tyrosine kinases and conven-
tional approved drugs such as Gem has proven effective in
both preclinical and clinical settings [8,10,11].
A pivotal role of the non-receptor tyrosine kinase FAK has
been demonstrated in a variety of human tumors by
Effects of FRNK overexpression on LN-mediated Gem chemoresistance Figure 10
Effects of FRNK overexpression on LN-mediated Gem chemoresistance. Parental AsPC-1 cells and vector-trans-
fected (Vector) and pcDNA3.1-FRNK-transfected (Pool) clones were treated with Gem (0.1 μM) for 72 h. Cell apoptosis was 
examined by Hoechst staining (the arrow indicates the apoptotic cells) (A), flow cytometry analysis of Annexin-V labeling(B) 
and western blot analysis of cleaved caspase-3 protein expression(C). Bars represent the mean of three independent experi-
ments ± SE. *, P < 0.05, vs. parental cells on plastic; #, P < 0.05, vs. parental cells or vector cells on LN. D, After plated on LN 
for 24 h, western blot analysis was used to detect the expression of Bad, p-Bad (pS136), p-Bad (pS112), Bcl-2, Bax and survivin 
in parental AsPC-1 cells and vector and pool clones on LN. Parental cells on plastic were used as control. The membranes 
were probed with anti-β-actin antibody to ensure even loading of proteins in each lane.Molecular Cancer 2009, 8:125 http://www.molecular-cancer.com/content/8/1/125
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Effects of PF-228 on the phosphorylation of FAK, Akt and ERK in pancreatic cancer cells Figure 11
Effects of PF-228 on the phosphorylation of FAK, Akt and ERK in pancreatic cancer cells. A, Panc-1 cells were 
treated with or without the indicated concentrations of PF-228 for 1 h. B, After pretreated with or without the indicated con-
centrations of PF-228 for 30 min in serum-free medium, suspended AsPC-1 cells were plated onto plastic or LN-coated plates 
for 1 h in the continued presence or absence of PF-228. Western blot showed expression of pFAK (pY397), p-Akt (pS473), p-
ERK 1/2 and their total proteins in the cells. The membranes were probed with anti-β-actin antibody to ensure even loading of 
proteins in each lane.
Effects of PF-228 on Gem-induced apoptosis in Panc-1 cells Figure 12
Effects of PF-228 on Gem-induced apoptosis in Panc-1 cells. Panc-1 cells were pretreated with or without PF-228 (1 
μM) for 1 h and then treated with or without 10 μM Gem for 72 h in the continued presence or absence of PF-228. The cells 
were subjected to apoptosis analysis by Hoechst staining (the arrow indicates the apoptotic cells) (A), flow cytometry analysis 
of Annexin-V labeling (B) and western blot analysis of cleaved caspase-3 protein expression (C). Bars represent the mean of 
three independent experiments ± SE. *, P < 0.05, vs. Panc-1 cells without Gem treatment; #, P < 0.05, vs. Gem-treated Panc-1 
cells without PF-228 pretreatment.Molecular Cancer 2009, 8:125 http://www.molecular-cancer.com/content/8/1/125
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expression or phosphorylation is elevated in ovarian,
breast, head and neck, thyroid, esophageal, colon, liver
and pancreatic cancers, indicating that FAK might be a
novel therapeutic target and prognostic marker for these
malignancies [12,13,17,23]. Consistent with a previous
study [17], all four pancreatic cancer cell lines that we
tested showed high FAK expression at the protein level. In
recent studies, researchers have begun to hypothesize that
FAK is a key determinant of chemoresistance since the
modulation of FAK function through antisense oligonu-
cleotides or RNAi influences the sensitivity of different
kinds of tumor cells to various chemotherapeutic agents
[15,16,34]. Herein, we examined whether constitutive
FAK protein expression in pancreatic cancer cells corre-
lated with the intrinsic chemoresistance to Gem or 5-FU.
However, our study showed total FAK protein expression
which was similar among all four cell lines, did not corre-
late with Gem or 5-FU chemoresistance. It has also been
reported previously that FAK protein expression might not
be a prognostic marker for pancreatic cancer patients [17].
Tyrosine 397 is the major site of autophosphorylation in
FAK. Phosphorylation at Tyr397 correlates with increased
catalytic activity of FAK and is important for tyrosine
phosphorylation of focal-adhesion-associated proteins
[35,36]. Our study here showed that constitutive pFAK
(pY397) levels positively correlated with Gem chemore-
sistance in pancreatic cancer cell lines. This indicates that
the phosphorylated active form of FAK may be of greater
biological significance compared with the total expres-
sion.
We demonstrated herein that specific RNAi against FAK
reduced FAK expression, decreased FAK phosphorylation
and thus suppressed the intrinsic chemoresistance to Gem
in Panc-1 cells, which had a high level of pFAK (pY397).
Our results indicate that FAK is a potential target for pan-
creatic cancer treatment. The C-terminal non-catalytic
domain of FAK termed FRNK functions as a competitive
inhibitor of FAK and ectopic expression of FRNK specifi-
cally inhibits FAK autophosphorylation at Tyr397 and
thus attenuates its activity [19,20]. In our study, FRNK
overexpression enhanced Gem-induced cytotoxicity and
apoptosis to a similar extent as FAK RNAi in Panc-1 cells.
However, FRNK overexpression did not significantly affect
Effects of PF-228 on LN-mediated Gem chemoresistance in AsPC-1 cells Figure 13
Effects of PF-228 on LN-mediated Gem chemoresistance in AsPC-1 cells. After pretreated with or without PF-228 
(1 μM) for 30 min in serum-free medium, AsPC-1 cells were plated onto plastic or LN-coated 6-well plates and treated with 
Gem (0.1 μM) for 72 h in the continued presence or absence of PF-228. Cell apoptosis was examined by Hoechst staining (the 
arrow indicates the apoptotic cells) (A), flow cytometry analysis of Annexin-V labeling(B) and western blot analysis of cleaved 
caspase-3 protein expression(C). Bars represent the mean of three independent experiments ± SE. *, P < 0.05, vs. AsPC-1 cells 
without Gem treatment; #, P < 0.05, vs. Gem-treated AsPC-1 cells without PF-228 pretreatment on LN.Molecular Cancer 2009, 8:125 http://www.molecular-cancer.com/content/8/1/125
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Gem-induced apoptosis in AsPC-1 cells that had low level
of pFAK (pY397). These results demonstrate that constitu-
tive FAK phosphorylation contributes to the intrinsic
chemoresistance to Gem in pancreatic cancer cells. Previ-
ous study in breast cancer cells has also found that FRNK
overexpression inhibited the activation of FAK and PKB
and thus enhanced chemotherapy-induced cell apoptosis
[37]. Small molecule inhibitors of FAK phosphorylation
(such as PF-573,228, PF-562,271, TAE226, 1,2,4,5-Ben-
zenetetraamine tetrahydrochloride) have been developed
in recent years [22,38-40]. PF-562,271 is a potent inhibi-
tor of both FAK and the related kinase Pyk2, while
TAE226 is an effective inhibitor of both FAK and insulin-
like growth factor I receptor [38]. Therefore, a commer-
cially available and more specific inhibitor of FAK phos-
phorylation, PF-228, was chosen in our study. Compared
with FRNK, PF-228 can more specifically block FAK auto-
phosphorylation both in normal and tumor cells. As
expected, inhibition of constitutive FAK phosphorylation
by PF-228 also decreased the intrinsic chemoresistance to
Gem in Panc-1 cells. It further confirms the role of consti-
tutive FAK phosphorylation in the intrinsic chemoresist-
ance to Gem in pancreatic cancer cells and indicates
development of selective FAK phosphorylation inhibitors
may be a promising way to enhance chemosensitivity in
pancreatic cancer. Interestingly, FRNK overexpression or
PF-228 alone did not induce apoptosis in pancreatic can-
cer cells. Consistent with this, a previous study reported
that PF-228 had no effect on the growth or apoptosis of
normal or cancer cells [22].
In recent years, ECM proteins such as LN, fibronectin and
collagen I have been thought to be associated with the
intrinsic chemoresistance of many cancers. This phenom-
enon called CAM-DR represents a novel intrinsic pathway
for evading drug-induced apoptosis [23,25,26,41]. Previ-
ous data have also shown that α6β1 integrins, major LN-
binding receptor, are highly expressed in pancreatic cancer
tissues and cell lines, including AsPC-1 [25,42]. Our study
demonstrated that LN preventedAsPC-1 cells from Gem-
induced cytotoxicity and apoptosis. It indicates that CAM-
DR might be an important intrinsic chemoresistance
mechanism in pancreatic cancer. Moreover, it has also
been reported that Type I collagen reduced apoptosis of
AsPC-1 cells in response to 5-FU [43]. FAK functions as a
critical intracellular mediator in the ECM-integrin-initi-
ated signaling pathway [44,45]. Our studies found that
LN induced FAK phosphorylation in a time-dependent
manner in AsPC-1 cells, and FAK phosphorylation inhibi-
tion by either RNAi or FRNK overexpression antagonized
the effect of LN on Gem chemoresistance. The role of LN-
induced FAK phosphorylation in LN-mediated Gem
chemoresistance was further confirmed by using the more
specific inhibitor of FAK phosphorylation, PF-228. These
results indicate that induced FAK phosphorylation is
involved in LN-mediated chemoresistance to Gem and
further confirm FAK as a promising therapeutic target in
pancreatic cancer. Targeted therapy against FAK by meth-
ods such as using specific phosphorylation inhibitors
could potentially be used to inhibit the cell-ECM interac-
tion and thus suppress CAM-DR.
Akt and ERK are key downstream effectors of FAK in medi-
ating cell survival [44,46,47]. Upon integrin binding to
ECM or other stimuli, FAK is autophosphorylated at
Tyr397, which provides a high-affinity docking site for
several proteins including the p85 subunit of PI3K and the
Src kinase. Src can further phosphorylate FAK at several
additional sites, including Tyr925. The phosphorylation
of Tyr397, as well as of Tyr925, creates a binding site for
the Grb2-SOS complex which then permits signaling to
the RAS-MAPK cascade [35]. Our research showed that
specific inhibition of constitutive FAK phosphorylation
decreased Akt but not ERK phosphorylation in Panc-1
cells. Similarly, in Aspc-1 cells, LN-induced FAK phospho-
rylation was accompanied by Akt but not ERK activation,
and specific inhibition of FAK phosphorylation decreased
LN-induced Akt activation. These data indicate that Akt
might be involved in the intrinsic chemoresistance medi-
ated by FAK phosphorylation. These results are supported
by previous reports that the PI-3K-Akt pathway was
responsible for Gem chemoresistance in pancreatic cancer
in vivo and in vitro. Moreover, PI-3K-Akt has also been
shown to be involved in CAM-DR in small cell lung cancer
[26,48].
Apoptosis-associated proteins have been reported to
relate with chemoresistance in malignant tumors includ-
Effects of PF-228 on the expression of apoptosis-associated  proteins in pancreatic cancer cells Figure 14
Effects of PF-228 on the expression of apoptosis-asso-
ciated proteins in pancreatic cancer cells. A, Panc-1 
cells were treated with or without the indicated concentra-
tions of PF-228 for 24 h. B, After pretreated with or without 
the indicated concentrations of PF-228 for 30 min in serum-
free medium, AsPC-1 cells were plated onto plastic or LN 
for 24 h in the continued presence or absence of PF-228. 
Western blot analysis was used to detect the expression of 
Bad, p-Bad (pS136), p-Bad (pS112), Bcl-2, Bax and survivin. 
The membranes were probed with anti-β-actin antibody to 
ensure even loading of proteins in each lane.Molecular Cancer 2009, 8:125 http://www.molecular-cancer.com/content/8/1/125
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ing pancreatic cancers [29-32]. Pro-apoptosis protein Bad
is modulated by phosphorylation at two sites, Ser112
(ERK-dependent) and Ser136 (Akt-dependent). Phospho-
rylation prevents Bad from binding either Bcl-2 or Bcl-XL
and thus suppresses apoptosis. Inhibition of phosphor-
ylation at either site might sensitize tumor cells to chem-
otherapy [31,49]. In our study, corresponding with the
alteration of Akt, pBad (pS136) was regulated by constitu-
tive and induced FAK phosphorylation in pancreatic can-
cer cells. In addition, survivin exression was also regulated
by FAK phosphorylation. These data imply that pBad and
survivin might contribute to the intrinsic chemoresistance
mediated by constitutive and LN-induced FAK phosphor-
ylation.
Conclusions
Our research demonstrates for the first time that both con-
stitutive and LN-induced phosphorylation of FAK contrib-
ute to the intrinsic chemoresistance to Gem in pancreatic
cancer cell lines. This effect may be partially due to the reg-
ulation of Akt signaling pathway and apoptosis-associated
proteins. Our results suggest that FAK can be an attractive
therapeutic target for pancreatic cancer, and the develop-
ment of selective FAK phosphorylation inhibitors may be
a promising way to enhance Gem chemosensitivity in
pancreatic cancer.
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